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Introduction
The incidence of the metabolic syndrome is rising across the world, presenting patients and society with an increasing need for transformative therapies to treat this cluster of comorbidities. Patients who suffer from Diabetic Nephropathy (DN), a form of chronic kidney disease that is linked mechanistically to diabetes and the metabolic syndrome, are in acute need of disease modifying treatment options that will delay or prevent the progression to end stage renal disease (Gallagher and Suckling, 2016) . The etiology of this disease progression is complex because of an interplay between systemic metabolic and vascular dysfunctions that involves both tubular and glomerular renal systems; this has made the rational identification of novel disease modifying therapeutic targets difficult (Vallon and Komers, 2011) . We have chosen to focus on targets where there is a concordance between genetic loci associated with disease and evidence of efficacy in preclinical models; one potential therapeutic target that satisfies these two criteria is the protein kinase, adenosine monophosphate-activated protein kinase (AMPK) (Hallows et al., 2010; Kottgen et al., 2010) .
AMPK is a heterotrimeric kinase that is activated by changes in cellular energy levels, leading to phosphorylation of its target proteins, which include Acetyl-CoA carboxylase, TSC2, Raptor, TBC1D1, and PGC1α, resulting in increased energy production and reduced energy consumption (Mihaylova and Shaw, 2011) . AMPK has been studied in many organ systems and has been actively pursued as a therapeutic target for metabolic syndrome, in part because of the observation that elevated nutrient status results in low AMPK activity (Steinberg and Kemp, 2009) . Reduced phosphorylation of the AMPK α subunit at the activating threonine 172 site has been observed in renal glomeruli of diabetic patients, suggesting that low AMPK activity in the diabetic state could be part of the etiology of DN progression (Dugan et al., 2013) .
Multiple interventional studies in rodent models of diabetic kidney disease have suggested the potential benefits of activating AMPK for DN. Many of these studies utilized activators of AMPK JPET #237925 then diluted to 8% DMSO in buffer and five μL was transferred to a white assay plate. To this mixture, five µL of AMPK enzyme diluted in assay buffer was added to the assay plate (0.25nM, 0.25nM, 0.5nM, 2nM, 1nM, 1nM final for human AMPK α1β1γ1, rat AMPK α1β1γ1, human AMPK α1β2γ1, human AMPK α2β1γ1, human AMPK α2β2γ1 and human AMPK α2β2γ3 respectively) and incubated at room temperature for 15 minutes. Next, five µL of PP2a (2.5nM, 2.5nM, 5.0nM, 0.25nM, 0.25nM, 0.25nM final for AMPK α1β1γ1, rat AMPK α1β1γ1, human AMPK α1β2γ1, human AMPK α2β1γ1, human AMPK α2β2γ1 and human AMPK α2β2γ3 respectively) diluted in assay buffer was added and the plate was incubated for an additional 60 minutes. PP2a was selected not only for its activity against pAMPK, but also for its ability to be inhibited by okadaic acid, a potent inhibitor that does not interfere with the assay technology.
The phosphatase treatment was terminated and the kinase reaction initiated with the addition of 5 µL of okadaic acid (50nM final, Calbiochem, San Diego, CA), Cy5-SAMS peptide and ATP diluted in assay buffer. The kinase reactions were incubated for 60 min at room temperature and terminated by the addition of 10mM EDTA and 2 nM Eu-pACC antibody in LANCE Detection Buffer (Perkin Elmer, Waltham, MA). Kinase activity was monitored by excitation at 320 nm and measuring emission at 665 and 615 nm, respectively using EnVision® multilabel reader (Perkin Elmer) in TR-FRET mode. The final ratio of fluorescence emissions at wavelengths 665/615 nm (emission from phosphorylated SAMS peptide/emission from the europium antibody) was used to calculate the percent effect relative to the AMP and DMSO controls. The percent effect values were then plotted against the concentrations of compound and the EC 50 values were calculated using GraphPad prism software.
Protection Assay
The ability of AMPK activators to protect pAMPK from dephosphorylation was determined using Dissociation-Enhanced Lanthanide Fluorescent Immunoassay technology (DELFIA®). Briefly,
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test compounds were incubated with fully phosphorylated biotin acceptor peptide (BAP)-tagged AMPK in assay buffer consisting of 50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl 2 , 0.25 mM DTT, 0.01 % Tween-20 and 0.01% BSA. PP2a was then added to the mixture and allowed to proceed for 60 min at room temperature to dephosphorylate the AMPK protein by about 70%.
Reactions were terminated by the addition of okadaic acid and the mixture was transferred to a DELFIA® streptavidin-coated 384 well white plate and allowed to incubate with gentle shaking for 1 hour at room temperature. Wells were washed 6 times and captured AMPK was probed with primary anti-α subunit-pThr172 antibody for 45 min with gentle shaking at room temperature, and then washed 5 times as above. Wells were probed with DELFIA® Eu-N1 labeled anti-rabbit antibody for 45 min with gentle shaking and washed as above. The signal was developed by the addition of DELFIA® enhancement solution and time-resolved fluorescence was measured using an EnVISION TM plate reader (PerkinElmer) with the factoryset DELFIA® europium protocol (excitation at 340 nm and emission at 615 nm).
Determination of the mechanism of activation
Steady state kinetic experiments to determine the mechanism of allosteric activation of the compounds were performed by monitoring incorporation of 33 P-phosphate from 33 P-ATP into the SAMS peptide substrate as previously described (Calabrese et al., 2014; Rajamohan et al., 2015) .
Crystallization and Refinement:
The α1β1γ1 crystallization construct of rat AMPK was expressed and purified as previously described with the exception of a single mutation of Asn109 in the β1 subunit to His as is found in the human protein (Calabrese et al., 2014) . His109 lies in the vicinity of the allosteric binding site, but the limited resolution of the X-ray diffraction data do not permit detailed analysis of the subtle differences in the structure caused by this mutation. Lysine 29 of the alpha subunit is JPET #237925 modeled in a conformation similar to previous observations although electron density is not welldefined for the side chain.
Crystallization was carried out by sitting drop vapor diffusion by mixing equal volumes of protein (~11 mg/mL) and precipitant. Crystallization conditions consisted of a grid around the base condition of 100 mM trisodium citrate, 500 mM ammonium sulfate, 900 mM lithium sulfate, and 4% glycerol. Crystals grew over the course of 3-10 days at approximately room temperature.
In order to determine the structure with PF-249, crystals were soaked overnight in mother liquor supplemented with 400 μM AMP, 400 μM Staurosporine, and 500 μM PF-249 with 10%
glycerol. For cryoprotection, crystals were transferred to an identical solution containing 28%
glycerol. Data was collected at the IMCA-CAT beamline at APS and were processed using HKL2000 (Otinowski and Minor, 1997) . Structure was solved by molecular replacement using our previous structure (4QFR) as a search model. Refinement and rebuilding were carried out using autoBUSTER and Coot and figures were generated using PyMOL (Schrodinger) (Blanc et al., 2004; Emsley and Cowtan, 2004) . Nucleotides on the gamma subunit were modeled as previously described and subject to the same caveats (Calabrese et al., 2014) .
Quantification of β1 AMPK
Kidney samples were collected from C57Bl6J mice (Jackson Labs), Wistar-han rats (Charles River), and cynomologus non-human primates, and post-motem human (Analytical Biological Services, Inc). The rodent tissue samples were immediately snap-frozen in liquid nitrogen.
Primate samples were collected during necropsy and frozen on dry ice. Human kidney samples were acquired in collaboration with the Cleveland Clinic (Cleveland, OH), and Cornell University (Ithaca, NY). The amount of β1 and β2 AMPK was quantified using a modified version of the ThermoFisher Scientific AMPK Phospho-ELISA Kit. Kidney lysate from three species was added to the microwells of two plates pre-coated with an AMPKα mouse antibody.
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Recombinant human α1β1γ1 AMPK was used as a standard curve on one plate. To detect β1
AMPK, rabbit anti-AMPK β1 (4 ug/mL) was added to each well. One the second plate, recombinant human α2β2γ1was used as a standard curve. To detect β2 AMPK, rabbit anti-AMPK β2 (4 ug/mL) was added to each well. Anti-rabbit IgG, HRP-linked antibody was then used to recognize the bound detection antibody. HRP substrate, TMB, was added to develop color. The magnitude of the absorbance was measured at 450 nm. The standard curve was plotted for each plate and data were interpolated to the β1 or β2 standard curves, respectively, and PF-06409577 were prepared in DMSO and cells were treated with a final concentration of 1 μM and 3 μM with 0.1% final DMSO concentration. Cells pre-treated with both the controlscrambled siRNA and the PRKAB1 siRNA were dosed with either DMSO or compound. After 1 hour, cells were rinsed with PBS and lysed in ice-cold lysis buffer. Protein content was quantified by a bicinchoninic acid (BCA) based protein assay.
Lysate was prepared for western blot analysis by adding reducing agent and lithium dodecyl sulfate and boiling for 10 minutes. Samples were loaded onto two identical Bis-Tris gel and run at 200 volts for 60 minutes. BisTris gels were blotted on to a nitrocellulose membrane for 60 minutes at 30 volts, following a standard wet transfer protocol. Membranes were blocked in 5%
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non-fat milk prepared in Tris-Buffered Saline (TBS). After one hour, membranes were washed and antibody prepared in 5% Bovine Serum Albumin prepared in TBS with 0.1% Tween-20.
Rabbit anti-Pan α AMPK antibody and Rabbit anti-β1 and β2 AMPK antibody were incubated overnight at 4°C. Membranes were washed and incubated with Anti-Rabbit IgG, HRP-linked antibody diluted in 5% non-fat milk in TBS. After one hour, membranes were washed, enhanced chemiluminescent substrate was added, and membranes were developed in bright-field white light.
Cell culture and siRNA treatment was repeated. Protein content was quantified. Phosphorylated (Serine 79) ACC and total ACC protein levels were quantified using two electrochemiluminescent immunoassay based on the technologies provided by Meso Scale Discovery (Rockville, MD). Cell lysates were added to streptavidin coated plates and incubated for 2 hours at 37°C. To detect phosphorylated (Ser79) ACC or total ACC levels, AntiphosphoACC (Ser79) Rabbit polyclonal antibody (Millipore #07-303, at 2 ug/mL) or Anti-ACC Rabbit monoclonal antibody (Cell Signaling Technologies #3676, at 1 mg/mL) were use, respectively. SULFO-TAG™ labeled Goat Anti-Rabbit antibody was then used to recognize the bound detection antibody. MSD Read Buffer was added to initial the electrochemiluminescent reaction. The magnitude of the luminescence was measured using the SECTOR S600 plate reader.
ZSF1 Rat Studies
All animal experiments were conducted following study protocols and procedures reviewed and approved by Pfizer Institutional Animal Care and Use Committee. The facilities that supported this work are fully accredited by AAALAC International. For each study, six week-old, male ZSF1 lean and ZSF1 obese rats (Charles River, Wilmington, MA) were acclimated to the vivarium for 14 days prior to measurement of body weight and baseline evaluation of urine. Six
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days later, obese rats were assigned to one of five groups based upon urine albumin creatinine ratio (Siemens Advia 2400), urine protein creatinine ratio (Siemens Advia 2400), body weight, 24-hour urine albumin (Siemens Advia 2400), and urine volume (supplemental Table 4 ). Daily administration of 0.5% methylcellulose (p.o.), PF-06409577 at 10, 30, or 100 mg/kg (p.o.), PF-249 at 3, 10, or 30 mg/kg (p.o.), or ramipril in drinking water (~1 mg/kg/day) (Zoja et al., 2011) was initiated and continued for 68 days. Urine was collected for 24-hours and volume recorded from all lean and obese rats after 14, 28, 42, and 60 days of dosing. On Day 63 all rats were administered a final dose after 16-hour overnight fasting. One hour following the final dose, blood glucose was measured by glucometer (AlphaTrak 2, Zoetis) and a 100 μl tail vein blood sample collected and processed for determination of insulin levels (Alpco) and total protein (Advia 2400, Siemens). Each rat was then anesthetized with isoflurane. The right kidney was collected and immediately freeze-clamped and transferred to liquid nitrogen storage; the left kidney was fixed in 10% formalin. Rats were then euthanized by exsanguination from the vena cava.
In a separate study, blood pressure was monitored continually in 14-week old, telemeterized male, obese ZSF1 rats at were administered vehicle or PF-06409577 at 10, 30 or 100 mg/kg (p.o.) (n=10/group) for 14 days. Fifteen minute intervals of data from each animal was grouped into blocks of time, 0-2, 2-4, 4-8, 8-12, 12-16, 16-20 , and 20-24 hours post dose. Statistical analysis will compare the variances of data for drug treated and vehicle animals at each time block (adjusted for baseline) using ANOVA at days 1, 6, and 14.
Kidney Gene Expression
Tissue was pulverized under frozen conditions and 30 mg lysed in 1 mL of Qiazol reagent (Qiagen, USA) using MP Biomedical Lysing Matrix D tubes. 0.2 mL of chloroform (Sigma Aldrich, USA) was added and tubes were disrupted by vortexing. Samples were then spun at JPET #237925 10,300 rpm at 4°C for 15 minutes to ensure phase separation. 0.2 mL of the upper aqueous phase was then placed in a gDNA eliminator column (Qiagen, USA) and eluted. The sample was mixed with 0.2 mL of fresh 70% ethanol, and the sample was added to a 96-well RNeasy plate (Qiagen, USA) vacuum system. The wash procedure included in the RNeasy kit was then followed, and the final sample was eluted in 60 mL of RNase-free water. RNA concentration and purity was evaluated using a NanoDrop ND-8000 spectrophotometer (ThermoFischer, USA).
RNA was then diluted for a concentration of 100 ng per 10 μl, matched with 10 μl of High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems, USA). cDNA was then processed on a GeneAmpk PCR System 9700 according to kit directions. 400 ng of cDNA sample, Taqman primers (Applied Biosystems, USA) and TaqMan Fast Universal PCR Master
Mix (Applied Biosystems, USA) was loaded onto 384-well PCR reaction plates (Applied Biosystems, USA) and run on a Viia 7 PCR system. Analysis was performed to determine reference gene outliers, and Ct values were transformed into relative quantification data. The delta Ct was generated by removing the background of the housekeeping gene from the sample of interest. Results were then generated using the comparative delta delta Ct method and were normalized to the obese vehicle treated animals. Genes were normalized to PPIa mRNA.
Urine Analysis
All urine samples were centrifuged to pellet sediment and stored at -80°C prior to analysis.
Kim1/Tim1 was measured using the Quantikine RAT TIM-1/KIM-1 Immunoassay R&D Systems Cat# RKM100. Samples were diluted four fold and manufacturer's protocol followed with samples values calculated based on the provided KIM1 standards. TBAR assay was purchased from R&D Systems, Cat#KGE013, and used at a 1:2 dilution of urine according to manufacturer's protocol. TIMP1 was measured with Sigma Aldrich ELISA, cat#RAB0470, using a 20 fold dilution of urine and following the manufacturer's protocol. Creatinine, total protein,
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This article has not been copyedited and formatted. The final version may differ from this version. minutes at room temperature. Positive staining was detected by using Leica's Refine Polymer kit which includes an anti-rabbit polymer and diaminobenzidine (DAB) for visualization. All slides were counterstained with hematoxylin, dehydrated through a series of graded alcohols and xylenes, and mounted with cover slips. Additionally, a rabbit isotype control (Vector Laboratories, Burlingame, CA) was run in parallel using all the same pretreatment and detection steps.
Microscope slides with kidney sections stained for pS6 were scanned on the Leica/Aperio AT2 whole slide digital scanner at the 20X objective setting. Images were saved in .svs format and stored in Aperio eSlide Manager image database.
An image analysis rule set was created in Definiens Tissue studio that allowed for the manual outline of individual glomeruli. Manual outlines of glomeruli were sampled from three uniform Lysate was stored at -80°C for future use.
pAMPK/tAMPK Assay Methods
Phosphorylated (Threonine 172) AMPK and total AMPK protein levels were quantified using a modified version of the solid phase sandwich enzyme-linked immunosorbent assay (ELISA) from Cell Signaling Technologies. Kidney tissue lysates were added to microwells pre-coated with an AMPKα rabbit antibody. Fully phosphorylated recombinant human α2β2γ1AMPK was used as a standard curve. To detect Thr172 phosphorylation or total AMPK levels, antiphospho AMPK (Thr172) mouse antibody or anti-AMPK β mouse antibody were used, respectively. Anti-mouse IgG, HRP-linked antibody was then used to recognize the bound detection antibody. HRP substrate, 3,3',5,5'-Tetramethylbenzidine (TMB), was added to develop color. The magnitude of the absorbance was measured at 450 nm. The standard
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curve was plotted and data were interpolated to the standard curve using SoftMax Pro. The ratio of phosphorylated to total AMPK protein were calculated.
Statistical Analysis
Statistics were calculated in GraphPad Prism. One way or two way Anova was performed and multiple comparison analysis done to evaluate significance between indicated groups. * indicates p<0.05, ** p<0.01, *** p<0.001, and **** p<0.0001.
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Results
PF-06409577 and PF-249 are selective activators of AMPK β1-containing heterotrimers
Using a novel AMPK assay format to measure the activation and protection of the AMPK α1β1γ1 heterotrimer, we determined the EC 50 for PF-06409577 to be 6 nM (human); 5 nM (rat), and for PF-249 to be 9 nM (human); 5 nM (rat). Both compounds were also tested against the human α1β2γ1, α2β2γ1, and α2β2γ3 heterotrimers, showing weak activity for each. (Figure 1a 
AMPK β1 is highly expressed in rodent and human kidney
The selectivity of the AMPK activators for β1-containing isoforms prompted us to quantify both the total and relative expression of AMPK isoforms across several species of interest. We observed that the β1 subunit is present in 93.1%, 95.5%, 33.3%, and 64.0% of all AMPK heterotrimers in the normal C57Bl6J mouse, Wistar Han rat, non-human primate, and human kidney, respectively. Across the four species we tested, mouse (158 pmol/g) contained the highest concentration of β1-containing isoforms, followed by rat (128 pmol/g), human (114 Table 4 ). Maximal doses for subsequent in vivo studies were selected by measuring kidney phosphoAMPK/total AMPK (pAMPK/tAMPK) ratios following a single, oral dose of either PF-06409577 or PF-249. Both compounds dose-dependently increased the pAMPK/tAMPK with PF-06409577 achieving a maximal response at 100 mg/kg (Cameron et al., 2016) ; PF-249 response plateaued at the 30 mg/kg dose (Supplemental Figure 2) Activation of AMPK β1-containing heterotrimers in a rat model of diabetic nephropathy altered the progression of proteinuria and improved urine biomarkers of kidney disease
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The ZSF1 rat is a commonly used in vivo model of DN as it exhibits many characteristics of the human disease (Bilan et al., 2011; Boustany-Kari et al., 2016) . We employed this model to evaluate whether direct activation of AMPK has an effect on proteinuria and the overall kidney function. Obese ZSF1 rats exhibited mild proteinuria at 8 weeks of age and progressed rapidly to more severe kidney dysfunction (Figure 3a) . Oral administration of PF-06409577 (10, 30, and 100 mg/kg QD) resulted in dose-dependent reductions in proteinuria in the obese ZSF1 animals, with greater than 2-fold reduction in 24-hour urinary albumin loss compared to vehicle control after 60 days of treatment (Figure 3a) . Histological assessment of the kidneys from these rats revealed a reduction in the presence of protein casts in the tubules of both PF-06409577 and ramipril treated animals, but we failed to rigorously identify improvements in glomerular structures of treated aniamals (Supplemental Figure 3) . Additionally, administration of PF-06409577 had no significant effect on the hyperglycemia and insulin resistance displayed by all groups of obese ZSF1 rats (Figure 3c-d) . Further, when the improvement in proteinuria was compared with the observed plasma drug exposure and corrected for plasma protein binding, the IC 50 for the effect was calculated to be 5.5 nM (Supplemental figure 3, 4 , and 5).
Moreover, the inhibitory effect on proteinuria correlated with a dose-dependent increase in kidney pAMPK levels (Figure 3b ).
We also assessed the impact of PF-06409577 on systemic blood pressure as a potential explanation for the improvement in kidney function in the ZSF1 rat in telemeterized animals. PF-06409577 delivered at 100 mg/kg had some modest reductions in systemic blood pressure at times during the day, but treatment did not cause a sustained and consistent effect ( Figure   3e -f).
To replicate our initial observation, the related AMPK activator PF-249 was compared with PF-06409577 and the Angiotensin Converting Enzyme inhibitor (ACEi), ramipril, in the same model.
As observed previously, progressive elevation in proteinuria in obese ZSF1 rats was attenuated JPET #237925
by both AMPK activators PF-06409577 and PF-249, the latter in a dose dependent manner following 68 days of dosing (Figure 4a) . Modeling of the dose-dependent improvements in proteinuria observed in this study, using the observed plasma drug exposure corrected for plasma protein binding, revealed an IC 50 for the effect of 32 nM for PF-249 and 14.5 nM for PF-06409577 (Supplemental figure 3, 6, and 7 ). The top dose tested for both AMPK activators resulted in a reduction of UACR, UPCR and 24-hour urinary albumin excretion equivalent to or greater than that achieved with ramipril ( Figure 4a and Table 1 ). These improvements in urinary albumin excretion were accompanied by AMPK activation in the kidney for animals treated with AMPK activators (Figure 4b ).
PF-06409577 and PF-249 improve mechanistic markers of kidney function
We explored additional endpoints to increase the understanding of the biological consequences of AMPK activation in the kidney that might account for the improvements in renal function.
Urinary levels of KIM1, a marker of general tissue damage, were reduced to a similar extent, >40% (P<0.01), by PF-249, PF-06409577, and ramipril (Table 1) . Urinary levels of TIMP1, a tissue metalloprotease inhibitor that is elevated in states of fibrosis, were elevated in obese animals with impaired kidney function and reduced (P<0.01) by PF-249 and PF-06409577 treatment, with the highest dose groups approaching the levels detected in lean animals with normal kidney function ( Table 1) . Ramipril also lowered (P<0.05) TIMP1, although to a lesser degree than the AMPK activators. Urinary thiobarbituric acid reactive substances (TBARs) are an indicator of reactive oxygen species (ROS)-mediated production of reactive lipid species in the setting of kidney dysfunction. As expected, the obese animals in these studies exhibited elevated urinary TBARs. Treatment with PF-249, PF-06409577, and ramipril reduced (P<0.01)
TBARs levels towards those observed in lean animals. In aggregate, these results demonstrated improvements to multiple facets of the diseased ZSF1 kidney, while revealing subtle differences in biological responses to AMPK activators compared with ramipril.
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PF-06409577 lowers glomerular mTOR signaling
Glomerular mTOR activity is an established driver of podocyte hypertrophy and compromised filtration barrier (Godel et al., 2011; Inoki et al., 2011; Inoki and Huber, 2012; Eid et al., 2013) .
AMPK is well-known to be negative regulator of mTORC1, raising the possibility that this mechanism could be responsible for the improvements in renal function observed in obese ZSF1 rats treated with AMPK activators. Phosphorylation state of ribosomal S6 kinase (p-S6) is a marker of mTOR activation that has been used histologically to evaluate glomerular mTOR signaling (Godel et al., 2011) . Histological assessment of obese ZSF1 kidneys revealed kidneys with increased p-S6 levels within the glomeruli (Figure 5a-d) , consistent with the above hypothesis. Treatment of obese ZSF1 animals with 100 mg/kg PF-06409577 reduced p-S6
within glomeruli to levels comparable to lean animals and significantly less than vehicle treated obese ZSF1 rats (Figure 5a-d) .
PF-06409577 and PF-249 impact kidney mRNA of mechanistic markers
To gain further insight into the mechanism(s) underlying the improvement in kidney function upon AMPK activation, mRNA expression was also evaluated in kidney tissue samples from the chronically treated ZSF1 rats. The potential of AMPK activation to modify fibrosis was assessed by exploring the expression of the Col1a1 and Col4a1 mRNAs that encode the major collagens.
Both transcripts were elevated in diseased animals, with PF-249 and PF-06409577 treatment reducing Col1a1(P<0.01) but not Col4a1 expression (Figure 6a-b) . It has been reported that AMPK activation reduces levels of the NADPH-oxidase Nox4 and this may be responsible for improvement of kidney function (Sharma et al., 2008; Eid et al., 2013) . In our studies Nox4 mRNA was not significantly elevated in the obese ZSF1 animals implying Nox4 is not a major contributor to renal dysfunction in this model (Eid et al., 2013) . Nevertheless, Nox4 mRNA was modestly decreased in the 30 mg/kg PF-249 dose group (P<0.05) (Figure 6c ).
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In diabetic kidney models the transcriptional regulator PGC1α, a well-known target of AMPK, has been linked to the modulation of mitochondrial function and the accompanying changes in the oxidative potential and ROS generation (Dugan et al., 2013) . While PGC1α mRNA was similar in the obese and lean ZSF1 groups, an increase in the PGC1α transcript was observed in the 30 mg/kg PF-249 treated animals (Figure 6d ). The modest changes in whole tissue mRNA levels of the markers of kidney disease in this study may be ascribed to the multiple cell types comprising the nephron. Consequently, these mRNA-based transcriptomics studies were inconclusive in defining a specific mechanism downstream of AMPK activation responsible for the observed improvements in kidney function.
pressure dynamic, and glomerular sclerosis, it is unlikely that a single protective mechanism underlies the observed pharmacological effects.
The selective small molecule activators of AMPK β1-containing heterotrimers described here dramatically improve renal function in a rodent model of diabetic nephropathy. These results suggest that activators of AMPK warrant further testing as a treatment for human diabetic nephropathy, and potentially other kidney diseases that remain inadequately treated by existing medicines.
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